Clinical Trial Update: Phase I/II Trial of Pembrolizumab and Androgen-receptor Inhibitor With or Without 225Ac-J591 for Progressive Metastatic Castration Resistant Prostate Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase I/II trial evaluating Pembrolizumab in combination with an androgen-receptor inhibitor, with or without 225Ac-J591, for progressive metastatic castration-…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• 225Ac-J591 (Actinium-225-labeled J591)
• KEYTRUDA (PEMBROLIZUMAB)
• androgen receptor inhibitor

Snippet

Sponsor: Weill Medical College of Cornell University | Conditions: Prostate Cancer | Phase 1, Phase 2 | Status: RECRUITING